<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03357172</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A03267-48</org_study_id>
    <nct_id>NCT03357172</nct_id>
  </id_info>
  <brief_title>Determination of Factors Involved in the Regulation of Immune Responses After Allogeneic Hematopoietic Stem Cell Transplantation</brief_title>
  <acronym>REAL-GREFFE</acronym>
  <official_title>Determination of Factors Involved in the Regulation of Immune Responses After Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study concerns donors and patients receiving allogeneic stem cell haematopoietic
      transplantation. The aim of the study is to analyse HSC graft content in immune effector T
      (naive, memory, activated, exhausted) and immunoregulatory cell subtypes (Tregs, iNKT, MDSC)
      and correlate the results with post-transplant immune reconstitution of those different cell
      subtypes and clinical events (graft-versus-host-disease, relapse, infections). An ancillary
      study will focus on the impact of microbiota dysbiosis on post-transplant immune response and
      regulatory cell subsets.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportions of regulatory immune cells in peripheral blood.</measure>
    <time_frame>After 7 days, 15 days, 21 days, 30 days, 60 days, 90 days, 180 days, 1 year, 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of graft versus host (GVH) reaction after allografting of CSH</measure>
    <time_frame>After 7 days, 15 days, 21 days, 30 days, 60 days, 90 days, 180 days, 1 year, 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse</measure>
    <time_frame>After 7 days, 15 days, 21 days, 30 days, 60 days, 90 days, 180 days, 1 year, 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections</measure>
    <time_frame>After 7 days, 15 days, 21 days, 30 days, 60 days, 90 days, 180 days, 1 year, 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progress-free survival</measure>
    <time_frame>After 7 days, 15 days, 21 days, 30 days, 60 days, 90 days, 180 days, 1 year, 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>After 7 days, 15 days, 21 days, 30 days, 60 days, 90 days, 180 days, 1 year, 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Allogeneic Hematopoietic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Recipient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Donor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood Sample</intervention_name>
    <description>Additional blood sample before graft, D0, D7, D15, D21, D30, D60, D90, D180, Y1, Y2</description>
    <arm_group_label>Recipient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bone marrow aspiration</intervention_name>
    <description>Additional bone marrow aspiration before graft, D30, D90, Y1</description>
    <arm_group_label>Recipient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Before donation</description>
    <arm_group_label>Donor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic hematopoietic stem cell sample</intervention_name>
    <description>Allogeneic hematopoietic stem cell sample</description>
    <arm_group_label>Donor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient of the Nancy CHRU, for whom a CSH allograft is planned. or

          -  hematopoietic stem cell donors received at Nancy's CHRU for the duration of the
             research

        Exclusion Criteria:

          -  Positive HIV

          -  active hepatitis B or C infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marie-Thérèse RUBIO, PU-PH</last_name>
    <phone>0383153257</phone>
    <phone_ext>+33</phone_ext>
    <email>m.rubio@chru-nancy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU de Nancy</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Thérèse RUBIO, Pr</last_name>
      <phone>0383153030</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 24, 2017</study_first_submitted>
  <study_first_submitted_qc>November 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2017</study_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immune recovery</keyword>
  <keyword>Immunomodulatory cells</keyword>
  <keyword>GVHD</keyword>
  <keyword>GVL</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

